Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
|
| Abstract |
In Langerhans cell histiocytosis (LCH), somatic gene mutations in the mitogen-activated protein kinase pathway have been identified in more than 80% of cases in Western countries, in which mutually exclusive BRAF and MAP2K1 mutations are involved. Among them, BRAF V600E mutation is the major contributor (50-60%). In 59 patients (50 children and nine adults) with LCH (not including pulmonary LCH) in Japan, we first screened for BRAF V600E in all patients followed by target sequencing for other gene mutations in 17 of BRAF V600E-negative patients. As a result, BRAF V600E mutation was detected in 27/59 (46%) patients. We also identified BRAF mutations other than V600E in five and MAP2K1 mutations in nine patients. Thus, gene mutations in BRAF or MAP2K1 were identified in 41/44 (93%) of the fully tested patients. Regarding the correlation of clinical features and genotype in pediatric patients, we found that BRAF V600E mutation status was not correlated with sex, age at diagnosis, disease extent, response to first-line therapy, relapse, or CNS-related sequelae. Interestingly, MAP2K1 exon 2 in-frame deletion was related to the risk organ involvement; however, further studies are required to clarify the impact of these gene mutations on the clinical features of patients with LCH.
|
|---|---|
| Authors | Tomomi Hayase, Shiori Saito, Yoko Shioda, Toshihiko Imamura, Kenichiro Watanabe, Kentaro Ohki, Takako Yoshioka, Yukiko Oh, Yuta Kawahara, Hitomi Niijima, Shinsaku Imashuku, Akira Morimoto |
| Journal | International journal of hematology (Int J Hematol) Vol. 112 Issue 4 Pg. 560-567 (Oct 2020) ISSN: 1865-3774 [Electronic] Japan |
| PMID | 32654047 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!